Temozolomide and Fluid retention - a phase IV clinical study of FDA data

Summary:

Fluid retention is reported as a side effect among people who take Temozolomide (temozolomide), especially for people who are male, 60+ old, also take Decadron, and have Headache.

The phase IV clinical study analyzes which people have Fluid retention when taking Temozolomide. It is created by eHealthMe based on reports of 16,598 people who have side effects when taking Temozolomide from the FDA, and is updated regularly.

What is Temozolomide?

Temozolomide has active ingredients of temozolomide. It is often used in glioblastoma multiforme. eHealthMe is studying from 16,644 Temozolomide users. Check the latest studies of Temozolomide.

What is Fluid retention?

Fluid retention (an abnormal accumulation of fluid in the blood) is found to be associated with 1,702 drugs and 2,446 conditions by eHealthMe. Check the latest studies of Fluid retention.

On Aug, 02, 2026

16,598 people reported to have side effects when taking Temozolomide.
Among them, 27 people (0.16%) have Fluid retention.

Could Temozolomide cause Fluid retention?

Among these 27 people:

What is the gender of people who have Fluid retention when taking Temozolomide? *

female: 22.22 %
male: 77.78 %

What is the age of people who have Fluid retention when taking Temozolomide? *

What are other drugs people take besides Temozolomide? *

What are other side effects people have besides Fluid retention? *

Weight Increased: 12 people, 44.44%
Dyspnea (difficult or laboured breathing): 9 people, 33.33%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 8 people, 29.63%
Chest Pain: 5 people, 18.52%
Malaise (a feeling of general discomfort or uneasiness): 4 people, 14.81%
Pain: 4 people, 14.81%
Fatigue (feeling of tiredness): 4 people, 14.81%
Cough: 3 people, 11.11%
Rebound Effect (take-back effect): 3 people, 11.11%
Headache (pain in head): 3 people, 11.11%

What are the existing conditions these people have? *

Headache (pain in head): 4 people, 14.81%
Central Nervous System Lymphoma (cancer of central nervous system forms in lymph tissue): 3 people, 11.11%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 2 people, 7.41%
Oligodendroglioma (a type of glioma that are believed to originate from the oligodendrocytes of the brain or from a glial precursor cell): 2 people, 7.41%
Neuroendocrine Tumor: 2 people, 7.41%
Pancreatic Neuroendocrine Tumor Metastatic: 1 person, 3.70%
Nuclear Magnetic Resonance Imaging Brain: 1 person, 3.70%
Neuroblastoma (a cancer that forms in your nerve tissue): 1 person, 3.70%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 1 person, 3.70%
Brain Neoplasm Malignant (brain cancer tumour): 1 person, 3.70%

* Approximation only. Some reports may have incomplete information.

Do you take Temozolomide and have Fluid retention?

- Check whether Fluid retention is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Temozolomide:

Temozolomide (16,644 reports)

Fluid retention treatments and more:

Fluid retention (79,660 reports)

Browse all side effects of Temozolomide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fluid retention:

Fluid retention (1,702 drugs)

Browse all the conditions that are associated with Fluid retention:

Fluid retention (2,446 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on temozolomide (the active ingredients of Temozolomide) and Temozolomide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.